Sage Journals: Discover world-class research

Abstract

Duchenne muscular dystrophy is a severe X-linked inherited muscle wasting disorder caused by mutations in the dystrophin gene. Adeno-associated virus (AAV) vectors have been extensively used to deliver genes efficiently for dystrophin expression in skeletal muscles. To overcome limited packaging capacity of AAV vectors (<5 kb), truncated recombinant microdystrophin genes with deletions of most of rod and carboxyl-terminal (CT) domains of dystrophin have been developed. We have previously shown the efficiency of mRNA sequence–optimized microdystrophin (ΔR4-23/ΔCT, called MD1) with deletion of spectrin-like repeat domain 4 to 23 and CT domain in ameliorating the pathology of dystrophic mdx mice. However, the CT domain of dystrophin is thought to recruit part of the dystrophin-associated protein complex, which acts as a mediator of signaling between extracellular matrix and cytoskeleton in muscle fibers. In this study, we extended the ΔR4-23/ΔCT microdystrophin by incorporating helix 1 of the coiled-coil motif in the CT domain of dystrophin (MD2), which contains the α1-syntrophin and α-dystrobrevin binding sites. Intramuscular injection of AAV2/9 expressing CT domain–extended microdystrophin showed efficient dystrophin expression in tibialis anterior muscles of mdx mice. The presence of the CT domain of dystrophin in MD2 increased the recruitment of α1-syntrophin and α-dystrobrevin at the sarcolemma and significantly improved the muscle resistance to lengthening contraction–induced muscle damage in the mdx mice compared with MD1. These results suggest that the incorporation of helix 1 of the coiled-coil motif in the CT domain of dystrophin to the microdystrophins will substantially improve their efficiency in restoring muscle function in patients with Duchenne muscular dystrophy.

Get full access to this article

View all access options for this article.

References

Ahn

A.H.

, Kunkel

L.M.

1995. Syntrophin binds to an alternatively spliced exon of dystrophin. J. Cell Biol., 128:363–371.

Arechavala-Gomeza

, Kinali

, Feng

et al. 2010. Immunohistological intensity measurements as a tool to assess sarcolemma-associated protein expression. Neuropathol. Appl. Neurobiol., 36:265–274.

Athanasopoulos

, Graham

I.R.

, Foster

, Dickson

2004. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD) Gene Ther., 11,Suppl. 1S109–21.

Blake

D.J.

, Tinsley

J.M.

, Davies

K.E.

et al. 1995. Coiled-coil regions in the carboxy-terminal domains of dystrophin and related proteins: potentials for protein-protein interactions. Trends Biochem. Sci., 20:133–135.

Blake

D.J.

, Weir

, Newey

S.E.

, Davies

K.E.

2002. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev., 82:291–329.

Brenman

J.E.

, Chao

D.S.

, Gee

S.H.

et al. 1996. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by Pdz domains. Cell, 84:757–767.

Campbell

K.P.

1995. Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell, 80:675–679.

Crawford

G.E.

, Faulkner

J.A.

, Crosbie

R.H.

et al. 2000. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J. Cell Biol., 150:1399–1410.

Emery

A.E.H.

, Muntoni

2003. Duchenne muscular dystrophy. Oxford University Press: Oxford, 270.

10.

Fabb

S.A.

, Wells

D.J.

, Serpente

, Dickson

2002. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum. Mol. Genet., 11:733–741.

11.

Foster

, Sharp

P.S.

, Athanasopoulos

et al. 2008. Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer. Mol. Ther., 16:1825–1832.

12.

Fuentes-Mera

, Rodriguez-Munoz

, Gonzalez-Ramirez

et al. 2006. Characterization of a novel Dp71 dystrophin-associated protein complex (DAPC) present in the nucleus of HeLa cells: members of the nuclear DAPC associate with the nuclear matrix. Exp. Cell Res., 312:3023–3035.

13.

Gee

S.H.

, Madhavan

, Levinson

S.R.

et al. 1998. Interaction of muscle and brain sodium channels with multiple members of the syntrophin family of dystrophin-associated proteins. J. Neurosci., 18:128–137.

14.

Grady

R.M.

, Grange

R.W.

, Lau

K.S.

et al. 1999. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat. Cell Biol., 1:215–220.

15.

Gregorevic

, Blankinship

M.J.

, Allen

J.M.

, Chamberlain

J.S.

2008. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol. Ther., 16:657–664.

16.

Hosaka

, Yokota

, Miyagoe-Suzuki

et al. 2002. Alpha1-syntrophin-deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration. J. Cell Biol., 158:1097–1107.

17.

Kameya

, Miyagoe

, Nonaka

et al. 1999. Alpha1-syntrophin gene disruption results in the absence of neuronal-type nitric-oxide synthase at the sarcolemma but does not induce muscle degeneration. J. Biol. Chem., 274:2193–2200.

18.

Kobayashi

Y.M.

, Rader

E.P.

, Crawford

R.W.

et al. 2008. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature, 456:511–515.

19.

Koenig

, Hoffman

E.P.

, Bertelson

C.J.

et al. 1987. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell, 50:509–517.

20.

Lai

, Yue

, Liu

et al. 2005. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat. Biotechnol., 23:1435–1439.

21.

Lai

, Thomas

G.D.

, Yue

et al. 2009. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J. Clin. Invest., 119:624–635.

22.

, Eastman

E.M.

, Schwartz

R.J.

, Draghia-Akli

1999. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol., 17:241–245.

23.

, Sun

, Wang

et al. 2008. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum. Gene Ther., 19:958–964.

24.

Muntoni

, Torelli

, Ferlini

2003. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol., 2:731–740.

25.

Newey

S.E.

, Benson

M.A.

, Ponting

C.P.

et al. 2000. Alternative splicing of dystrobrevin regulates the stoichiometry of syntrophin binding to the dystrophin protein complex. Curr. Biol., 10:1295–1298.

26.

Petrof

B.J.

, Shrager

J.B.

, Stedman

H.H.

et al. 1993. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U. S. A., 90:3710–3714.

27.

Sadoulet-Puccio

H.M.

, Rajala

, Kunkel

L.M.

1997. Dystrobrevin and dystrophin: an interaction through coiled-coil motifs. Proc. Natl. Acad. Sci. U. S. A., 94:12413–12418.

28.

Sherratt

T.G.

, Vulliamy

, Strong

P.N.

1992. Evolutionary conservation of the dystrophin central rod domain. Biochem. J., 287,Pt 3:755–759.

29.

Suzuki

, Yoshida

, Ozawa

1995. Mammalian alpha 1- and beta 1-syntrophin bind to the alternative splice-prone region of the dystrophin COOH terminus. J. Cell Biol., 128:373–381.

30.

Thomas

G.D.

, Shaul

P.W.

, Yuhanna

I.S.

et al. 2003. Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. Circ. Res., 92:554–560.

31.

Tinsley

J.M.

, Blake

D.J.

, Zuellig

R.A.

, Davies

K.E.

1994. Increasing complexity of the dystrophin-associated protein complex. Proc. Natl. Acad. Sci. U. S. A., 91:8307–8313.

32.

Turk

, Sterrenburg

, De Meijer

E.J.

et al. 2005. Muscle regeneration in dystrophin-deficient mdx mice studied by gene expression profiling. BMC Genomics, 6:98.

33.

Williams

J.C.

, Armesilla

A.L.

, Mohamed

T.M.

et al. 2006. The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J. Biol. Chem., 281:23341–23348.

34.

Yan

, Lei-Butters

D.C.

, Zhang

et al. 2007. Hybrid adeno-associated virus bearing nonhomologous inverted terminal repeats enhances dual-vector reconstruction of minigenes in vivo. Hum. Gene Ther., 18:81–87.

35.

Yoshimura

, Sakamoto

, Ikemoto

et al. 2004. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol. Ther., 10:821–828.

36.

Yue

, Liu

, Duan

2006. C-terminal-truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/dystrophin double-knockout mice. Mol. Ther., 14:79–87.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.21 MB

Delivery of AAV2/9-Microdystrophin Genes Incorporating Helix 1 of the Coiled-Coil Motif in the C-Terminal Domain of Dystrophin Improves Muscle Pathology and Restores the Level of α1-Syntrophin and α-Dystrobrevin in Skeletal Muscles of mdx Mice

Abstract

Get full access to this article

References

Supplementary Material